AMENDMENTS TO THE CLAIMS:

Please cancel claim 30 without prejudice.

Please add new claims 31-34.

Please amend claims 21, 23, 25-27 and 29 as follows:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. **(Original)** A method for inhibiting a cancerous phenotype of a cell, said method comprising ÷ contacting a cancerous mammalian cell with an agent for inhibition of DKFZ5661133 activity.

2. **(Original)** The method of claim 1, wherein said test cell is a breast cell.

3. **(Original)** The method of claims 1-2, wherein said cancerous phenotype is aberrant cellular proliferation relative to a normal cell.

4. **(Original)** The method of claims 1-3, wherein said cancerous phenotype is loss of contact inhibition of cell growth.

5. **(Original)** The method of claims 1-4, wherein said agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

6. **(Original)** The method of claims 1-6, wherein said inhibition is associated with a reduction in a level of DKFZp5661133 protein.

7. **(Original)** The method of claims 1-7, wherein said inhibition is associated with a reduction in a level of DKFZ5661133 RNA.

8. **(Original)** The method of claims 1-8, wherein said inhibition is associated with a reduction in a level of activity of DKFZ5661133 protein.

9. **(Original)** A method for detecting a cancerous cell, said method comprising:

detecting a level of DKFZp5661133 or fragment thereof in a test sample obtained from a cell of a subject,

comparing the level of DKFZp5661133 to a control level of DKFZ5661133,

wherein the presence of a cancerous cell is indicated by detection of said level and comparison to a control level of DKFZ5661133.

10. **(Original)** The method of claim 9, wherein said cancerous cell is a cancerous breast cell.

11. **(Original)** The method of claims 9-10, wherein said gene product is nucleic acid.

12. **(Original)** The method of claims 9-1 1, wherein said gene product is a polypeptide.

13. **(Original)** The method of claims 9-12, wherein said detecting step uses a polymerase chain reaction.

14. **(Original)** The method of claims 9-13, wherein said detecting step uses hybridization.

15. **(Original)** The method of claims 9-14, wherein said sample is a sample of breast tissue.

16. **(Original)** The method of claims 9-1 5, wherein said level of said product is indicative of the cancerous state of the cell of the test sample.

17. **(Original)** A method of treating a subject with cancer, said method comprising: administering to a subject a pharmaceutically effective amount of an agent, wherein said agent modulates the activity of DKFZ5661133.

18. **(Original)** The method of claim 17, wherein said cancer is breast cancer.

19. (**Original**) The method of claims 17-18, wherein said agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

20. (**Original**) A method for assessing the tumor burden of a subject, said method comprising: detecting a level of DKFZp5661133 in a test sample from a subject, wherein the level of DKFZp5661133 in the test sample is indicative of the tumor burden in the subject.

21. (**Currently amended**) A method for identifying an anti-cancer agent that modulates a biological activity of a gene product differentially expressed in a cancerous cell as compared to a normal cell, said method comprising:

contacting a candidate anti-cancer agent with a cell that expresses DKFZp5661133; and

detecting a difference between the biological activity of DKFZp5661133 in the presence and absence of the candidate anti-cancer agent, wherein a difference between the level of biological activity of DKFZp5661133 in the presence and absence of the candidate anti-cancer agent indicates that the candidate anti-cancer agent has anti-cancer activity ~~modulation of a biological activity of DKFZp5661133 relative to a level of biological activity of DKFZp5661133 in the absence of the candidate agent~~ .

22. (**Original**) The method of claim 21, wherein said cancerous cell and said normal cell are breast cells.

23. (**Currently amended**) The method of claim 21 ~~claims 21-22~~, wherein said detecting is by assessing expression of said gene product.

24. (**Original**) The method of claim 23, wherein expression is assessed by detecting a polynucleotide gene product.

25. (**Currently amended**) The method of claim 23 ~~claims 23-24~~, wherein expression is assessed by detecting a polypeptide gene product.

26. (**Currently amended**) The method of either of claim 21 or claim 32 ~~claims 21-25~~,

wherein said candidate agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

27. **(Currently amended)** The method of claim 21 ~~claims 21-26~~, wherein said biological activity is modulation of a cancerous phenotype.

28. **(Original)** The method of claim 27, wherein said cancerous phenotype is abnormal cellular proliferation.

29. **(Currently amended)** The method of claim 27 ~~27-28~~, wherein said cancerous phenotype is loss of contact inhibition.

Claim 30 **(Cancelled)**

31. **(New)** The method of either of claim 21 or claim 32 wherein the agent is a polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:508 and SEQ ID NO:510.

32. **(New)** A method of screening a candidate agent for anti-cancer activity comprising:

(a) contacting a cell that expresses DKFZp5661133 with a candidate agent; and

(b) detecting a difference between the level of expression of DKFZp5661133 in the presence and absence of the candidate agent, wherein a difference between the level of DKFZp5661133 expression in the presence and in the absence of the candidate agent indicates that the candidate agent has anti-cancer activity.

33. **(New)** The method of claim 32 wherein a difference in expression levels of DKFZp5661133 is detected using a polymerase chain reaction, hybridization, or Western blot.

34. **(New)** The method of either of claims 21 or 32 wherein the cancer is breast cancer.